
News|Videos|August 1, 2024
Generics and Biosimilars in Multiple Sclerosis
Key opinion leaders explore the impact of newly available biosimilars and generic biologics for managing multiple sclerosis (MS), discussing how these developments have altered patient access to treatments and the implications for the future of the MS treatment landscape.
Advertisement
Episodes in this series

- Generics or biosimilar versions of many MS treatments are now available.
- How has this changed access to MS treatment for patients?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
NRLP3 Inhibitor VTX3232 Well-Tolerated, Improves Parkinson Symptoms in Phase 2a Trial
2
Exploring the Role of Aerobic Exercise in Promoting Remyelination in Multiple Sclerosis: Lindsey Wooliscroft, MD, MS
3
Interim ROSSINI Data Highlight Foslevodopa/Foscarbidopa’s Impact in Advanced Parkinson Disease
4
Unmet Needs in Myasthenia Gravis Care
5